Was Sawai’s FDA approval for pitavastatin a Paragraph IV filing in 2017?
Yes. Records for Sawai Pharmaceutical’s pitavastatin filing indicate FDA approval tied to a Paragraph IV (P-IV) challenge in 2017, which is how generic entrants often resolve patent/market-exclusivity issues under the Hatch-Waxman framework. This type of filing typically means the applicant asserted that the referenced patent was invalid and/or not infringed, and FDA approval follows the statutory patent-exclusivity and litigation timing rules. [1]
What does “Paragraph IV” mean in the pitavastatin context?
A Paragraph IV certification is part of an Abbreviated New Drug Application (ANDA). It signals that the generic applicant is challenging a listed patent for the brand drug’s active ingredient/labeling, using a P-IV legal certification. If the patent challenge triggers litigation, it can delay certain generic approvals until specific time or court/litigation triggers occur (the exact timing depends on the case and statutory deadlines). [1]
Why would Sawai’s pitavastatin approval in 2017 matter?
A P-IV-based ANDA approval in 2017 matters because it can mark the point when the FDA allowed a generic to enter the market sooner than it would have without a successful patent challenge, subject to the usual Hatch-Waxman rules and any litigation outcomes. [1]
Where to verify the exact product/approval details (label, strengths, approval date)
To confirm the specific pitavastatin product and the exact approval date/label strengths, you typically check the FDA’s ANDA/Orange Book and associated FDA approval communications for the specific ANDA holder (Sawai) and the listed patents that were challenged under Paragraph IV. [1]
Sources
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm